Fiche centre
Research Site
Katowice — Poland
Essais liés8clinical trials
VilleKatowicelocalisation
PaysPolandlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07691970
Essais cliniques associés
8| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| BIIB033 (opicinumab) | SEP | Phase 2 | NCT03222973 | AFFINITY — Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) | TERMINATED |
| Anifrolumab | Myopathies | Phase 3 | NCT07691970 | ROSY-S — Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment | RECRUITING |
| Anifrolumab | Lupus | À vérifier | NCT06673043 | SLE-ARTEMIS — Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING |
| Baxdrostat/dapagliflozin | Hypertension | Phase 3 | NCT06742723 | BaxDuo-Pacific — A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure | RECRUITING |
| Anifrolumab | Lupus | Phase 3 | NCT07430306 | SUNFLOWER — A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus | RECRUITING |
| ALXN1720 | Myasthénie | Phase 3 | NCT05556096 | Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Medi-546 | Lupus | Phase 3 | NCT04877691 | Tulip SC — Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING |
| Ravulizumab | Myasthénie | À vérifier | NCT06909253 | MG-ARCADIA — Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis | RECRUITING |